Tobin Schilke, CFO at Revance Therapeutics, Inc. (RVNC), sold 3,701 shares at $25.00 ($101K) on 2023-01-09, disclosed to the SEC on 2023-01-10.
Scheduled sale ($101k) by CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.00 | 1,701 | $43K | 42.3% |
| 2 | $28.00 | 1,000 | $28K | 27.9% |
| 3 | $30.00 | 1,000 | $30K | 29.8% |
| Total | $27.16 avg | 3,701 | $101K | 100% |
| Filing → |
| RVNC | SELL | 2023-07-05 | $43K | — | Filing → |
| RVNC | SELL | 2023-06-05 | $181K | — | Filing → |
| RVNC | SELL | 2023-05-16 | $1.5M | — | Filing → |